Fosopamine

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Fosopamine ( ; developmental code names SIM-2055, Z-2055; also known as fosfenamine or N-methyldopamine 4-O-phosphate) is a dopamine receptor agonist of the phenethylamine and catecholamine families which was under development for the treatment of hypertension but was never marketed. It is taken orally. Fosopamine is a prodrug of epinine (N-methyldopaine) and is said to be selectively metabolized into epinine in the kidneys. The drug was being developed by AstraZeneca and Zambon Group SpA. It reached phase 2 clinical trials prior to the discontinuation of its development.

Fosopamine ( ; developmental code names SIM-2055, Z-2055; also known as fosfenamine or N-methyldopamine 4-O-phosphate) is a dopamine receptor agonist of the phenethylamine and catecholamine families which was under development for the treatment of hypertension but was never marketed. It is taken orally. Fosopamine is a prodrug of epinine (N-methyldopaine) and is said to be selectively metabolized into epinine in the kidneys. The drug was being developed by AstraZeneca and Zambon Group SpA. It reached phase 2 clinical trials prior to the discontinuation of its development.

See also

Neurotransmitter prodrug

References

Text derived from https://en.wikipedia.org/w/index.php?oldid=1328673375 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

3 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.